Medicenna Therapeutics Announces Participation in Upcoming Conferences

Core Insights - Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing Superkines for cancer and autoimmune diseases, participating in several upcoming conferences to showcase its innovative therapies and engage with the investment community [1][5]. Upcoming Conference Participation - Medicenna will participate in the Planet MicroCap Showcase in Toronto in 2025, BIO-Europe 2025 in Vienna, and the Oppenheimer Miami Oncology Summit [2][3][4]. - The BIO-Europe event is one of the largest life sciences partnering events, providing Medicenna a platform to engage with potential partners and investors [7]. - The Oppenheimer Miami Oncology Summit will focus on oncology advancements, allowing Medicenna to discuss its immunotherapy innovations [7]. Company Overview - Medicenna is developing novel, highly selective versions of IL-2, IL-4, and IL-13 Superkines, including the long-acting IL-2 Superkine, MDNA11, which preferentially stimulates cancer-killing effector T cells and NK cells [5]. - The IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials with over 130 patients, including a Phase 2b trial for recurrent GBM, and has received FastTrack and Orphan Drug status from the FDA and EMA [5]. - Medicenna's early-stage BiSKITs™ and T-MASK™ programs aim to enhance the effectiveness of Superkines in treating immunologically "cold" tumors [5].